Harvard Medical School researchers have found that statin use significantly reduces the risk of hepatocellular carcinoma (HCC ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

The FDA has issued a complete response letter for rivoceranib plus camrelizumab as a first-line treatment for unresectable ...

For patients with chronic liver disease, statin use is associated with a reduced risk for hepatocellular carcinoma (HCC) and ...

Despite resubmitting after an initial complete response letter (CRL) due to manufacturing issues, the combination therapy ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

An expert discusses how, for advanced unresectable hepatocellular carcinoma (uHCC), clinicians monitor treatment efficacy ...

The analysis included 16,501 participants: 3610 statin users and 12,891 nonusers. HealthDay News — For patients with chronic liver disease, statin use is associated with a reduced risk for ...

Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, accounts for about 75–85% of all liver cancer ...

Direct-acting antivirals (DAAs) have dramatically changed the landscape of chronic hepatitis C virus (HCV) treatment and ...

Residual cancer can remain undetected despite clear scans, potentially leading to worse outcomes and higher risks of ...

Despite appearing successful on scans, radiotherapy may leave behind undetected microscopic cancer cells, posing a greater ...